表皮生长因子受体基因突变对非小细胞肺癌脑转移患者生存期的影响

Effect of Epidermal Growth Factor Receptor Gene Mutation on Survival Time of Non-Small Cell Lung Cancer Patients with Brain Metastases

为了探究表皮生长因子受体(epidermal growth factor receptor,EGFR)基因的突变对非小细胞肺癌(non-small cell lung cancer,NSCLC)脑转移患者生存期的影响,我们以2012年1月至2014年12月期间我院收治的123例非小细胞肺癌脑转移患者为回顾性研究对象,按治疗方案的差异分为放射治疗组(36例),化疗组(52例),放射治疗+化疗组(24例)、放化疗+靶向治疗组(13例),观察EGFR基因突变对不同治疗方案的非小细胞肺癌脑转移患者无进展生存期(progression-free-survival,PSF)和总生存期(overall survival,OS)的影响。我们发现,EGFR突变对非小细胞肺癌脑转移患者生存期具有显著影响,EGFR突变型患者生存期明显长于EGFR野生型患者,而基于EGFR突变的靶向治疗患者生存期明显长于辅助治疗患者,因此基于EGFR突变的靶向治疗可有效提升患者生存期。我们的研究为非小细胞肺癌脑转移患者的临床治疗提供了一定的理论依据。

In order to understand the effect of epidermal growth factor receptor gene mutation on survival time of non-small cell lung cancer patients with brain metastases, 123 patients with non-small cell lung cancer admitted in our hospital from January 2012 to December 2014 were selected as the object of retrospective study. These patients were divided into radiotherapy group （36 cases）, chemotherapy group （52 cases）, radiotherapy＋chemotherapy group （24 cases）, radiotherapy and chemotherapy＋targeted therapy group （13 cases） to observe the influence of EGFR mutations on progression-free-survival time （PSF） and overall survival （OS） of patients under different treatments. It was suggested that EGFR mutations had a significant effect on the survival of patients with non-small cell lung cancer with brain metastases. The survival time of EGFR mutant patients was significantly longer than that of EGFR wild type patients. The survival time of patients with EGFR mutations was significantly longer than that of adjuvant patients. Mutation of targeted therapy could effectively improve the survival of natients.